Drug profile · INN
tisotumab vedotin-tftv
TIVDAK
tisotumab vedotin-tftv (TIVDAK) is a coagulation factor iii binding agent. Route of administration: injection. Current US regulatory status: approved.
Drug details — tisotumab vedotin-tftv
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
tisotumab vedotin-tftv (TIVDAK) is a coagulation factor iii binding agent. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Coagulation factor III binding agent
Primary target: Tissue factor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tisotumab vedotin-tftv?
tisotumab vedotin-tftv (TIVDAK) is a coagulation factor iii binding agent. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for tisotumab vedotin-tftv?
TIVDAK is a marketed brand name for tisotumab vedotin-tftv. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tisotumab vedotin-tftv?
tisotumab vedotin-tftv has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.